share_log

金斯瑞生物科技：海外監管公告: 上市附屬公司傳奇生物科技股份有限公司截至二零二四年六月三十日止半年度的財務業績及業務亮點

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT - FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30 JUNE 2024 AND BUSINESS HIGHLIGHTS OF A LISTED SUBSIDIARY - LEGEND BIOTECH CORPORATION

Hong Kong Stock Exchange ·  Aug 9 20:50
Summary by Futu AI
傳奇生物科技於2024年8月9日公佈其2024年第二季度未經審計財務業績，顯示CARVYKTI®（西達基奧侖賽；cilta-cel）的淨貿易銷售額約為1.86億美元。英國藥品和保健產品管理局（MHRA）和加拿大衛生部批准CARVYKTI®用於復發性來那度胺難治性多發性骨髓瘤成人患者的早期治療線。此外，公司表示截至2024年6月30日，現金及現金等價物、存款和短期投資達到13億美元，預計這些資金將提供直至2026年的財務儲備，並預計在2026年實現經營利潤。傳奇生物首席執行官黃穎博士對CARVYKTI®的發展勢頭表示樂觀，並期待比利時的Obelisc工廠開始商業化生產以滿足日益增長的需求。
傳奇生物科技於2024年8月9日公佈其2024年第二季度未經審計財務業績，顯示CARVYKTI®（西達基奧侖賽；cilta-cel）的淨貿易銷售額約為1.86億美元。英國藥品和保健產品管理局（MHRA）和加拿大衛生部批准CARVYKTI®用於復發性來那度胺難治性多發性骨髓瘤成人患者的早期治療線。此外，公司表示截至2024年6月30日，現金及現金等價物、存款和短期投資達到13億美元，預計這些資金將提供直至2026年的財務儲備，並預計在2026年實現經營利潤。傳奇生物首席執行官黃穎博士對CARVYKTI®的發展勢頭表示樂觀，並期待比利時的Obelisc工廠開始商業化生產以滿足日益增長的需求。
Legend Biotech announced its unaudited financial results for the second quarter of 2024 on August 9, 2024, showing a net trade sales of CARVYKTI® (cilta-cel) of approximately 0.186 billion US dollars. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have approved CARVYKTI® for early-line treatment of relapsed and refractory multiple myeloma in adult patients who have received at least one prior therapy. In addition, the company stated that as of June 30, 2024, cash and cash equivalents, deposits, and short-term investments amounted to 1.3 billion US dollars. These funds are expected to provide financial reserves until 2026, and the company expects to realize operating profits in 2026. Dr. Ying Huang, CEO of Legend Biotech, expressed optimism about the development of CARVYKTI® and looks forward to the commercial production at the Obelisc plant in Belgium to meet the increasing demand.
Legend Biotech announced its unaudited financial results for the second quarter of 2024 on August 9, 2024, showing a net trade sales of CARVYKTI® (cilta-cel) of approximately 0.186 billion US dollars. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have approved CARVYKTI® for early-line treatment of relapsed and refractory multiple myeloma in adult patients who have received at least one prior therapy. In addition, the company stated that as of June 30, 2024, cash and cash equivalents, deposits, and short-term investments amounted to 1.3 billion US dollars. These funds are expected to provide financial reserves until 2026, and the company expects to realize operating profits in 2026. Dr. Ying Huang, CEO of Legend Biotech, expressed optimism about the development of CARVYKTI® and looks forward to the commercial production at the Obelisc plant in Belgium to meet the increasing demand.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.